Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22230
Full metadata record
DC FieldValueLanguage
dc.contributor.authorO'Brien, T. R.en
dc.contributor.authorMcDermott, D. H.en
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorCarrington, M.en
dc.contributor.authorMurphy, P. M.en
dc.contributor.authorHavlir, D. V.en
dc.contributor.authorRichman, D. D.en
dc.date.accessioned2015-11-24T19:23:02Z-
dc.date.available2015-11-24T19:23:02Z-
dc.identifier.issn0269-9370-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22230-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAllelesen
dc.subjectAnti-HIV Agents/*therapeutic useen
dc.subjectChemokine CXCL12en
dc.subjectChemokines, CXC/geneticsen
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectGene Frequencyen
dc.subjectHIV Infections/*drug therapy/immunologyen
dc.subject*HIV-1/genetics/physiologyen
dc.subjectHumansen
dc.subjectIndinavir/therapeutic useen
dc.subjectLamivudine/therapeutic useen
dc.subjectLinkage Disequilibriumen
dc.subjectMaleen
dc.subjectPolymorphism, Genetic/*geneticsen
dc.subjectRNA, Viral/blooden
dc.subjectReceptors, CCR2en
dc.subjectReceptors, CCR5/geneticsen
dc.subjectReceptors, Chemokine/*geneticsen
dc.subjectReceptors, Cytokine/geneticsen
dc.subjectReverse Transcriptase Inhibitors/therapeutic useen
dc.subjectTreatment Outcomeen
dc.subjectZidovudine/therapeutic useen
dc.titleEffect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10839590-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractBACKGROUND: Both the natural history of HIV infection and the response to antiretroviral therapy are heterogeneous. Polymorphisms in chemokine receptor genes modulate the natural history of HIV-1 infection. In comparison with subjects with other genotypes, the prognosis for HIV-1-infected CCR5-delta32 heterozygotes is more favorable and that for CCR5 promoter allele 59029A homozygotes is less favorable. METHODS: HIV-1-infected adults with a CD4+ lymphocyte count > or = 200 cells x 10(6)/l and a plasma HIV RNA level > or = 1000 copies/ml were treated with indinavir, zidovudine and lamivudine for 6 months. HIV RNA levels were measured at 4-week intervals. Genotyping for chemokine receptor gene polymorphisms (CCR5-delta32, CCR5 59029A/G, CCR2-641) was performed. We examined whether the time to first HIV RNA < 200 copies/ml, frequency of viral suppression failure (HIV RNA > or = 200 copies/ml between weeks 16 and 28 of therapy), or reduction from the pre-treatment HIV RNA level differed by genotype. RESULTS: Time to first HIV RNA < 200 copies/ml was not predicted by genotype. Among 272 Caucasian patients, viral suppression failure was more common among patients with the CCR5 +/+ inverted question mark CCR2+/+ inverted question mark CCR5-59029 A/A genotype (28%) than among all other subjects combined (relative risk, 2.0; P = 0.06). After 24 weeks of therapy, genotype groups differed in the reduction of the HIV RNA level from baseline (P = 0.02); patients with the CCR5 +/+ inverted question mark CCR2+/+ inverted question mark CCR5-59029 A/A genotype had a mean reduction of 2.12 log10 copies/ml compared to 2.64 log10 copies/ml among all other groups combined. CONCLUSION: Polymorphisms in chemokine receptor genes may explain some of the heterogeneity in sustaining viral suppression observed among patients receiving potent antiretroviral therapy.en
heal.journalNameAIDSen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons